AstraZeneca’s immunotherapy Imfinzi has proven it can help certain patients with early-stage stomach cancer, according to ...

South Korean pharmaceutical and biotech companies are on track to exceed 10 trillion won ($7.5 billion) in licensing revenues ...

While activating ESR1 mutations are rare at the time of advanced breast cancer diagnosis, they emerge during first ... Safety ...

Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

LONDON, GREATER LONDON, UNITED KINGDOM, May 30, 2025 /EINPresswire.com/ -- What Is The Forecasted Growth Of The Sarcoidosis Market? The global sarcoidosis market has witnessed rapid growth in recent ...

Amgen's Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing ...

AstraZeneca Pharma shares rose on receiving nod from the CDSCO, to import for sale and distribution of Benralizumab 30 mg/ml ...